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PHARMACOTHERAPEUTICS TARGETING THE HEDGEHOG PATHWAY: 
EMERGING TREATMENTS FOR METASTATIC BASAL CELL CARCINOMA 
JOHN-MARK UNSWORTH 
ABSTRACT 
 Basal Cell Carcinoma (BCC) is one of the most commonly diagnosed 
nonmelanoma skin cancers (NMSC) in the world.  While BCC is usually readily treatable 
with surgical excision of the tumor, its metastatic form (mBCC) is far deadlier, with an 
average patient survival of eight months following diagnosis.  A majority of mBCC cases 
is tied to mutations causing dysfunction in the Hedgehog Pathway (HHP), a pathway that 
induces basal cells in the skin to divide rapidly and repeatedly.  For this reason, there has 
been an emphasis over the last thirty years on developing novel drug-based therapeutics 
for the treatment of mBCC that specifically target the HHP.  This paper will examine the 
body of published research investigating current and developing mBCC treatments, with 
a focus on the therapeutic modalities of the two current treatments for mBCC, 
Vismodegib and Sonidegib, and one potential treatment currently under investigation, 
Itraconazole/ATO.  A review of the clinical research will detail the mechanism of action 
for each drug with regard to the HHP and its components, the efficacy of the treatment, 
and adverse effects seen in patients during treatment. 
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BACKGROUND 
Classification of skin cancer 
Skin cancer can be divided into two major types: melanoma skin cancer and 
nonmelanoma skin cancer (NMSC).  Melanoma skin cancer is the most common of the 
two in the United States, with about two-thirds of all skin cancers falling into this 
category1,2.  NMSC constitute the other third of the cases2,3.  Two common subdivisions 
of NMSC are squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)4, and 
these are the two NMSCs with the highest reported prevalence worldwide in the last fifty 
years5. 
 BCC is a new and abnormal region of tissue growth or lesion in the uppermost 
part of human skin.  Skin is divided into three sections: the outermost epidermis overlays 
the dermis and hypodermis.  The epidermis is comprised of five layers: the stratum 
corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum, and the 
stratum basale.  Studies detailing the etiologic origin of BCCs have revealed that the 
stratum basale, also known as the basal layer, and the outer follicular root sheath are the 
two histologic sites from which BCC tumors originate6.  The outer follicular root sheath 
is continuous with the stratum basale, and encloses the hair shaft, through which hair 
grows, and the inner root sheath7.  The basal layer8 and the hair follicle7 are able to 
undergo regeneration.  There is still active research interrogating which cell type initiates 
tumor formation in BCC9.  Analysis of skin epidermis in the mouse model upon 
oncogenic signaling shows that only stem cells, and not progenitors, are capable of 
tumorigenesis10. 
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 There are multiple cell types in the innermost basal layer of the epidermis, 
including Merkel cells (which function as pressure receptors), melanocytes (which 
produce the pigment melanin), and basal cells (which are the most common cell type in 
the basal layer).  Basal cells are the stem cell of the epidermis and the precursor of 
keratinocytes; they are cuboidal and have larger nuclei and less cytoplasm11 than other 
basal layer cells.  Basal cell carcinoma simply defined is a skin tumor in these basal stem 
cells12. 
 Basal cells are the skin epithelial stem cells, which are mitotically active and 
divide and push up the cells above them to form the stratum spinosum.  Stem cells have 
the ability to renew themselves, and it is this unusual ability that makes stem cells, 
including the stem cells of the epithelial basal layer, a target for therapeutic research.  
Renewing epithelial tissues are kept in homeostasis by a small population of basal stem 
cells which can be separated from the epidermis and continue to give rise to new basal 
stem cells, or to any mature cell type of that tissue13.  Basal stem cells are difficult to 
identify and differentiate from surrounding basal layer cells14.  When a single cell from 
an excised section of the epithelial basal layer is tested, its proliferative potential ranges 
from a cell that cannot divide to a cell that can divide enough times to form a whole basal 
cell colony15. 
 The rate of growth of neoplasms in the basal layer is often slow, on the scale of 
years, with visually unchanged tumor appearance even after many years16.  Certain 
subtypes of these tumors, characterized by a large tumor size with a diameter greater than 
two centimeters11 are more aggressive in their expansion, and invade regions of the 
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surrounding tissue of the same layer.  Tumor size, histologic appearance, and invasive 
growth characterize the aggressive subtypes of tumors11,17. 
 Advanced basal cell carcinoma (aBCC) refers to two forms of BCC: locally 
advanced basal cell carcinoma (laBCC) and metastatic basal cell carcinoma (mBCC).  
Although BCC can be locally aggressive in the basement membrane of the epidermis, it 
almost always stays contained in that layer.  The progression of BCC to mBCC is rare8: 
its prevalence among BCC patients is less than one in one million18.  Metadata studies 
reviewing the incidence and epidemiology of all accepted cohorts of patients 
concurrently undergoing surgical treatments for BCC put the number of laBCC cases 
around one out of every thousand.  This work will focus on mBCC, and not on laBCC, 
which is currently poorly defined in the literature. 
Diagnosis 
The clinical morphology of BCC often presents as a lesion, which can be biopsied.  The 
morphological classification of BCC subtypes often depends on the gross anatomical 
region in which the lesion appears.  The four most common subtypes are 1) nodular, 
which are well defined and look like pearly white spots, 2) infiltrative, which are not well 
defined at their borders and contain ulcers, 3) superficial, which are erythematous and 
feature spots of redness which are often sore to the touch, and 4) mixed subtype, which 
features two or more than two tumors in the same lesion.  Additional designations can 
indicate cellular variations in pigment, nodule size, shape, location and depth19.  The 
most prevalent subtype is nodular BCC, which is often found in regions of the head and 
neck—areas that usually receive the most direct exposure to sunlight11,19. 
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 In order to diagnose BCC, the cellular morphology of the epidermal layer first 
needs to be identified.  A simple analysis of histological samples is sufficient for the 
morphological classification of BCC.  It is possible to differentiate between pathologic 
and benign BCC lesions over 95% of the time through the use of in vivo cutaneous 
surface microscopy, more commonly known as dermatoscopy20. 
Epidemiology and prevalence 
The number of diagnosed cases of skin cancer is steadily increasing.  Increased 
awareness of at-risk populations leads to more screening for carcinoma in those 
populations and an increase in skin cancer diagnosis.  Increased screening to detect 
carcinoma has boosted public awareness of carcinoma and its risk factors, which could 
lower the future incidence of carcinoma. 
 Twenty-five years ago the number of new NMSC cases documented annually in 
the United States was 700,00021.  Data from U.S. Medicare reports show that skin cancer 
procedures have seen a steady increase—in particular in the number of operations for 
NMSC, from 1.15 million in 1992 to 2.05 million in 20064.  A 13-state collaborative 
report from March of 2018 indicates that the numbers of diagnosed cases of BCC are 
continuing to increase, and this trend is projected to continue in the coming years3.  
Epidemiologic data indicate that global increases in the incidence of BCC will continue 
at a rate between 3 and 10 percent a year2,22.  On the regional scale, BCC is diagnosed at 
an increasing annual rate in both the United States3 and Europe, where it is expected to 
increase at a rate of 2 percent per annum, with increases as high as 30 percent for 
populations 85 years and older8. 
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 Skin color is the most important indicator for populations at risk for developing 
skin carcinomas.  In the white population BCC is the most prevalent cancer23.  BCC 
populations with darker skin color experience less than 1 percent of the global incidence 
of NMSCs5.  After adjusting for population and sample demographics, a global 
systematic review of BCC and SCC found that many of the countries in Africa, and the 
continent as a whole, experience the lowest incidence rate of the two major NMSCs5. 
 The highest prevalence of BCC occurs in regions where the dominant skin color 
is fairer and lighter.  Data show that the global incidence of BCC is highest in regions of 
the United States, Europe and Australia5,8.  Some models project that the rate of BCC 
incidence is increasing exponentially in countries where the majority of the population is 
fair skinned, especially in Australia and the United States8.  Almost all cases of BCC are 
seen in fair skinned individuals, and there is an increased risk for people with blonde or 
red hair, or people with blue, green or grey eyes22,24. 
 Among populations with similar color skin, geographic setting is a good indicator 
for the prevalence of BCC.  Regions that experience heavy annual sunshine show 
increased incidences of BCC, as do regions with proximity to the equator, with the 
highest rates seen in northernmost regions of Australia24. 
 Canada and Europe, lying at similar latitudes, report similar rates of BCC, as they 
are exposed to similar levels of ultraviolet radiation.  Arizona and New Mexico are two 
highly sun-saturated states that share a border in the southeast United States.  Their rates 
of BCC are high, about 930 per 100,000; there are comparable rates on the islands of 
Hawaii in the United States, which also experience a high degree of sunlight 
 6 
exposure21,25.  New Hampshire and Minnesota, more northern regions in the United 
States, experience less annual sunshine and share almost identical BCC rates, about 170 
per 100,0005. 
Sunlight/ultraviolet 
The increasing appearance of NMSCs like BCC is based on cumulative, lifetime 
exposures to certain risk factors integral to BCC development such as sunlight/ultraviolet 
light, increased age, genetic predisposition, and exposure to toxins.  However, there are 
some populations that show an increased susceptibility to BCC.  The incidence of BCC 
increases sharply with age.  BCC often begins to develop in individuals between the ages 
of 45 and 90, while the average age of those diagnosed with mBCC is 591,26.  Geriatric 
populations are already the most frequently diagnosed with BCC and the age-adjusted 
number of diagnoses continues to rise4,8. 
 The primary driving force of the pathogenesis and progression of BCC is 
ultraviolet light.  Ultraviolet radiation (UVR) is an electromagnetic wave of energy 
generated by the sun.  UVR is separated into two types: ultraviolet A radiation (UVAR) 
and ultraviolet B radiation (UVBR).  UVBR has a higher frequency than UVAR, and 
because frequency of a wave is directly proportional to its energy, UVBR is more 
dangerous, even though less UVBR is coming from the sun than the more common 
UVAR11,22.  There is a latency period of between 20 and 50 years from the time of 
exposure to harmful UVR and the appearance of clinically distinguishable BCCs22.  
Children under 20 with high levels of early-life recreational sun exposure show increased 
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incidence of BCC27.  Likewise, the use of tanning beds and the accompanying exposure 
to radiation has been linked to a 1.5 fold increase in BCC24. 
 Both UVR forms can damage deoxyribonucleic acid (DNA) but do so through 
different mechanisms.  UVAR is far more prevalent because it is a form seen in UVR 
exposure coming from natural light22.  UVAR can induce indirect damage to DNA 
because it triggers photooxidative stressors, which cause the generation of harmful 
reactive oxygen species in cells28.  UVBR is ten thousand times more mutagenic than 
UVAR22.  UVBR directly damages DNA by causing point mutations (transition 
mutations), which change a cytosine into a thymine.  In addition, two pyrimidines which 
are next to each other can be induced to form a covalent bond, creating pyrimidine 
dimers24.  Pyrimidine dimers in human DNA can only be repaired by nucleotide excision 
repair, where a segment of nucleotides on either side of the pyrimidine dimer is clipped 
out of the appropriate DNA sequence is then inserted by DNA repair machinery29. 
 If mutations are not repaired, they may contribute to oncogenesis depending on 
where in the genome the mutations occurred.  Mutations in intergenic regions or intron 
sequences may be harmless, but mutations in coding regions, in exons, or in regulatory 
elements such as promoters or repressors, may be harmful.  Genes damaged by ultraviolet 
light carry specific mutations, ultraviolet signatures identifying the causative source of 
the mutation30.  The majority of genes involved in BCC tumorigenesis show ultraviolet 
signature mutation patterns consistent with those induced through ultraviolet light.  These 
mutations can affect the function of tumor suppressor genes that regulate normal cellular 
growth and differentiation, oncogenes that can transform a normal cell into a tumor cell, 
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or cell regulatory genes that control the cell cycle31.  When these mutations affect the 
function of multiple tumor suppressor genes, oncogenes, and cell cycle genes, the cell 
cycle becomes misregulated and the basal cells are transformed31,32. 
Additional factors for BCC development 
Other risk factors may play a role in increased susceptibility to BCC.  Genetic disorders 
such as albinism and xeroderma pigmentosum can heighten an individual’s sensitivity to 
sun, and increase the risk of developing NMSCs8; having a family history of skin cancer 
positively correlates with BCC22,27, perhaps because people with a genetic link to skin 
cancer are predisposed to sun exposure sensitivity.  Exposure to arsenic has also been 
linked to the development of BCC, and other toxins may increase susceptibility to the 
incidence of BCC as well.  In addition, having freckles in childhood is correlated with an 
increase in the incidence of BCC8. 
 Radiation from a non-solar source is another known cause of NMSC.  Uranium 
miners and workers using early radiation generators both experience an elevated 
incidence of carcinogenic activity.  NMSC rates were high among the atomic bombing 
victims of Hiroshima and Nagasaki.  It remains unclear whether therapeutic radiative 
treatments can initiate either of the major NMSC carcinomas33. 
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INTRODUCTION OF HHP AND ITS ROLE IN BCC 
The hedgehog pathway 
The hedgehog pathway (HHP) components include the 12 transmembrane domain 
receptor protein Patched 1 (PTCH1); its three hedgehog protein ligands, Sonic hedgehog 
(SHH), Desert hedgehog, and Indian hedgehog; and the G-Coupled Protein-like receptor 
called Smoothened (SMO).  These proteins are involved in driving aberrant HHP 
signaling. 
 These HHP components are found in close proximity to the primary cilium (PC), 
which is an extension of the plasma membrane, built on a tubulin scaffold34.  The PC is a 
specific cellular compartment that is integral for the distribution and functioning of many 
elements of the HHP (Figure 1).  It is a specialized microtubule-based organelle that 
extends beyond the plasma membrane in almost every cell type, to detect extracellular 
signals32.  The core of the PC, called the basal body, spans the entire length of the 
extension and regulates the localization of HHP proteins, most notably PTCH1 and SMO, 
to and from the ciliary plasma membrane.  The basal body directs the movements of 
downstream pathway components as well, including the transcription factor proteins of 
the HHP and most of their regulatory proteins.  The ciliary concentrations of pathway 
components and their localization to various areas of the PC is what modulates HHP 
activity and signaling35.  The basal body is the means by which the components of the 
HHP interact with other components of the pathway, as well as with extracellular ligands 
such as drugs used for the treatment of mBCC, or the SHH ligand whose binding initiates 
the HHP signaling cascade. 
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Figure 1: Inhibition of Hedgehog Pathway Signaling.  The absence of SHH ligand 
binding to PTCH1 at the PC prevents the activation, ciliary accumulation, and signaling 
of SMO.  With the inhibition of SMO, SUFU sequesters the GLI transcription factors at 
the base of the basal body.  An increase in cAMP mediated by GPR161 promotes the 
sequential phosphorylation of GLI2 and GLI3 by PKA, CK1, and GSK3B, followed by 
proteasomal degradation, which truncates them into their repressor form.  GLI2R and 
GLI3R translocate to the nucleus where they bind to HH target genes and repress their 
transcription.  P = Phosphorylation; cAMP = Cyclic Adenosine Monophosphate; KIF7 = 
a kinesin protein mediating GLI2/3 movement in the PC35,36. 
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 SHH is the ligand active in the HHP activity of the basal cells of the skin, which 
line the basal layer of epithelial tissue.  The pathologic activation and signaling in these 
cells will eventually cause the lesions or tumors that are a hallmark of BCC.  The N-
terminus of the mammalian SHH ligand is its signaling domain, the region that binds 
PTCH134 and initiates HHP signaling.  SHH is an inactive ligand until it undergoes lipid 
modification to its N terminus37.  This modification is required for SHH binding to 
PTCH1 at the PC. 
 The PTCH1 protein exists in one of two forms: bound to the SHH ligand or in 
unbound form.  In the unbound form, the protein is localized at the base of the PC where 
it negatively regulates the activity and ciliary concentration of SMO35.  Consequently, no 
HHP signal can be transduced through the SMO transmembrane protein.  Concurrently, a 
putative endogenous small molecule SMO agonist is transported through the 
transmembrane channel of PTCH1 to the extracellular region where it cannot bind 
SMO13.  SHH binding to PTCH1 causes the translocation of PTCH1 from the PC, 
although the mechanisms for ciliary localization of PTCH1 to and from the PC are 
unclear.  The internalized protein and its ligand are tagged with ubiquitin and directed to 
the lysosome, where they undergo proteolytic degradation12. 
 PTCH1 activity is a matter of degree—not an all or nothing event—dependent 
upon the concentration of PTCH1 localized to the PC, the only place where PTCH1 has 
an effect.  The ciliary level or activity of PTCH1 can be modulated by cleaving its 
cytoplasmic tail that contains the ciliary localization signal37.  Increased PTCH1 ciliary 
expression is highly correlated with suppression of SMO activity37.  This is strong 
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evidence that PTCH1 has a role in negatively regulating SMO activity.  The ciliary 
decrease of PTCH1 upon SHH binding relieves its inhibition of SMO, and SMO can 
begin to accumulate at the plasma membrane of the PC.  SMO ciliary localization and 
activation are both necessary for SMO signaling, although the biochemical underpinnings 
that regulate of all three of these mechanisms remains unclear. 
 SMO is a GPCR-like protein, whose activation triggers an intracellular signal 
transduction cascade that increases the trafficking and processing of the glioma-
associated oncogene (GLI) transcription factors in the PC38.  Before SMO can enter the 
PC, it interacts with a protein called Discs large homolog 5, at the basal body of the PC 
extension.  This is a precursor step that is required for SMO activation39 but not required 
for the ciliary localization of SMO.  One prerequisite for SMO signaling downstream to 
the GLI proteins is the formation of a ciliary complex between SMO and the Ellis-van 
Creveld proteins 1 and 2; disabling this complex blocks signaling at some point in the 
pathway after SMO but before the GLI transcription factors40.  The mechanism by which 
pathway activation is communicated from SMO to the GLI proteins remains unclear. 
 There are at least two hypotheses postulated for the mechanism of action of SMO 
activation.  1) When PTCH1 is translocated into the cell and degraded, its dual inhibition 
of SMO is arrested: The putative endogenous SMO agonist accumulates inside the cell 
and SMO accumulates at the PC.  Intracellular increases of this small molecule agonist 
cause the activation of SMO, which is a prerequisite for the ciliary translocation of 
SMO34.  Following its activation the protein can translocate to the plasma membrane of 
the PC13.  SMO continues to accumulate at the PC as activation of HHP signaling 
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correspondingly increases37.  2) The key regulatory event of SMO activation is the 
binding of SHH to PTCH1, and not necessarily the removal of PTCH1 from the PC37.  
This suggests that increased production of the SHH ligand or increased activity in lipid 
modifications to the N-terminal domain of SHH will be key drivers of increasing SMO 
activity.  Whatever the mechanism that localizes SMO to the PC, its cytoplasmic domain 
has to interact with Ellis-van Creveld syndrome proteins 1 and 2, which allow for the 
transduction of the HHP signal35. 
 The degree of SMO activity is positively correlated with the degree of HHP 
activity and also regulates the form that the GLI transcription factors will take.  Activated 
SMO transduces the pathway signal through a signaling cascade that releases the GLI 
transcription factor proteins from cytoplasmic sequestration and induces them into their 
activator forms, which localize to the nucleus and bind the promoters of HHP genes 
inducing their transcription.  Inhibited SMO cannot transduce pathway signals and the 
GLI transcription factors remain sequestered in the cytoplasm until they are truncated 
into their repressor forms, which localize to the nucleus and bind the HHP genes and 
inhibit their transcription. 
 Downstream of SMO there are four important proteins that regulate the activity of 
the HHP by modulating the activity of the GLI transcription factors, most importantly 
GLI2 and GLI335.  These proteins include suppressor of fused (SUFU), kinesin family 
member 7 (KIF7), G-protein-coupled receptor 161 (GPR161), and protein kinase A 
(PKA). 
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 The interplay of the SUFU, KIF7, GPR161 and PKA proteins as a result of SMO 
inhibition causes the transcription factors GLI2 and GLI3 to be phosphorylated at the 
base of the basal body and undergo proteolytic degradation into their repressor forms, 
which translocate to the nucleus and repress the transcription of hedgehog (HH) target 
genes.  When PTCH1 remains unbound by the SHH ligand, PTCH1 remains in the PC 
and SMO is inhibited from translocating to the PC.  The protein SUFU binds the GLI 
transcription factors and is a negative regulator of HHP signaling, but only has its effect 
when SMO is not present and able to repress SUFU action.  When SMO is inhibited, 
SUFU binds to the GLI2 and GLI3 proteins at their C-terminal41 retention sequence.  
This causes GLI2 and GLI3 to be retained in the cytoplasm at the base of the basal 
body42–44.  KIF7 is a member of the kinesin family of motor proteins and regulates the 
movement of GLI2 and GLI3 within the PC.  When SMO is inhibited KIF7 is inactive, 
and it localizes to the base of the basal body and prevents the anterograde (base to tip) 
transport of SUFU, GLI2 and GLI3 to the top of the basal body.  GPR161 localizes to the 
base of the PC where its signaling cascade increases intracellular cAMP levels, which 
stimulates PKA activity45.  GLI2 and GLI3 undergo sequential phosphorylation by a set 
of kinases: PKA phosphorylates the transcription factors first, followed by subsequent 
phosphorylation by casein kinase I, and glycogen synthase kinase 3 beta46.  The 
phosphorylation sequence is followed by proteolysis during which the transcription 
factors are removed from SUFU by the centrosome-proximal proteasome12 into their 
repressor forms.  GLI2R and GLI3R translocate to the nucleus where they bind DNA and 
block transcription12 of HHP target genes47. 
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 The interplay of the SUFU, KIF7, GPR161 and PKA proteins as a result of SMO 
activation causes GLI2 and GLI3 to bypass phosphorylation and degradation and 
translocate to the nucleus in their activator forms, GLI2A and GLI3A48,49.  GLI2A and to a 
lesser extent GLI3A bind GLI-promoters in the nucleus and stimulate the transcription of 
HH target genes (Figure 2).  These activated HHP genes include PTCH1 and GLI1.  
Other cell-specific HHP genes are activated, and these mediate the wide range of cellular 
activities that are cell-specific in HHP activity12.  When PTCH1 is bound by the SHH 
ligand PTCH1 is displaced from the PC, and SMO translocates to the PC.  In the presence 
of activated SMO, SUFU is no longer able to sequester GLI2 and GLI3 at the basal body 
of the PC.  KIF7 is stimulated by SMO and moves via anterograde transport to the top of 
the basal body with SUFU, GLI2 and GLI3, which prevents the SUFU-mediated 
phosphorylation and degradation of GLI2 and GLI3.  GPR161 is also displaced from the 
PC as a result of SHH binding, which decreases the intracellular concentrations of cAMP.  
With a decrease in cAMP the activity of PKA is inhibited, and GLI2 and GLI3 are not 
phosphorylated by the kinases45.  GLI2 and GLI3 dissociate from SUFU as activators 
GLI2A and GLI3A and translocate to the nucleus where they target and turn on genes 
involved in the HHP47.  The genes are transcribed into messenger ribonucleic acid 
(mRNA) transcripts.  These mRNAs are translated into proteins which are directly 
involved in HHP signaling.  GLI transcription factors bind genes whose gene products 
are involved in cell fate determinants of tissue patterning, cellular proliferation, and 
regulators of cell survival50–52. 
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Figure 2: Activation of Hedgehog Pathway Signaling.  The presence of SHH ligand 
binding to PTCH1 results in the displacement of PTCH1 and GPR161 from the PC, and 
promotes the DLG5-mediated ciliary accumulation of SMO.  SMO forms a complex with 
EVC and EVC2 at the PC, which enables the transduction of HHP signaling.  The 
activation of SMO signaling leads to the release of SUFU-mediated cytoplasmic 
sequestration of the GLI transcription factors.  In the absence of GPR161, PKA is not 
activated, and GLI2 and GLI3 bypass both phosphorylation and subsequent truncation, 
and remain in full-length activator form.  GLI2A and GLI3A translocate to the nucleus 
where they bind to HH target genes and induce their transcription.  cAMP = Cyclic 
Adenosine Monophosphate35,36. 
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GLI transcription factors in pathway activity 
All nuclear events ascribed to HHP signaling occur through the three GLI transcription 
factors: GLI1, GLI2 and GLI3.  The predominant HHP activator and repressor are GLI1A 
and GLI3R, respectively, while GLI2 functions as both an activator and a repressor53.  All 
GLI proteins have activator forms and activation domains54, while only GLI2 and GLI3 
have a repressor domain54–56.  Once phosphorylated, GLI2 and GLI3 undergo proteolytic 
processing by the proteasome, which cleaves the proteins into their repressor forms 
GLI2R and GLI3R57–59.  When GLI2 and GLI3 avoid phosphorylation and proteolysis 
they act as full-length activators, GLI2A and GLI3A.  The full-length transcription factors 
GLI2A and GLI3A translocate to the nucleus where they bind the promoters of HHP 
genes.  This promotes transcription of context-specific genes, inducing genes specific to 
the HHP.  The activated genes begin the process of transcription, which produces mRNA 
transcripts. 
 The measured level of mRNA transcripts in a cell gives useful information about 
which GLI transcription factors are important in physiologic pathway activity, and which 
factors are important in pathologic pathway activity.  In physiologic HHP signaling, most 
GLI-dependent activation of HH target genes required for normal development is 
mediated by GLI2A47.  Samples from various pathologic BCC tissues show the 
accumulation of a high level of mRNA transcripts coding for GLI1, as well as for PTCH1 
and SMO60. 
 GLI1 expression correlates with HHP activity.  High expression of GLI1 is 
associated with aBCC, including mBCC.  Higher or lower levels of GLI1 are associated 
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with a better and worse mBCC prognosis, respectively46.  Unlike the other transcription 
factors GLI1 does not undergo proteolysis into a truncated non-activator form and is 
constitutively active in the HHP as GLI1A61.  Although GLI1 cannot be cleaved into a 
repressor form it can be degraded by the proteasome46.  A key HHP target is the GLI1 
gene, and its transcription depends on HHP signaling62,63.  The GLI1 gene encodes a 
feedforward pathway activator, which amplifies the initial HH signal at the level of 
transcription.  The measured levels of GLI1A mRNA are, consequently, a reliable 
indicator of HHP activity12.  Mutations at any level of HHP signaling, and most often at 
the level of PTCH1, SMO and SUFU, result in the increased expression of GLI1.  
Amplification of GLI1 is a key driver in tumorigenesis in BCC55. 
Physiologic pathway activity 
The HHP governs much of embryonic development and continues to function in adults, 
although to a lesser degree.  The mRNA transcripts that will code for proteins utilized in 
the HHP will localize to the cytosol, to begin the process of translation, which will result 
in proteins—the gene products of the HHP.  The gene products resulting from the 
transcription and translation of these genes are the proteins that are utilized in signaling in 
the HHP.  These proteins govern a wide range of HHP outcomes, and are key drivers of 
pathway-specific cellular activities, the most notable of which include tissue patterning, 
cellular proliferation, cell fate and cell differentiation50–52. 
 Some HHP proteins are translated in every cell type, other proteins are cell-
specific and will only be translated if that cell type receives the appropriate signal.  Each 
cell type will generate HHP-specific proteins, which mediate critical pathway activities.  
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The PTCH1 protein is a central pathway protein and functions to convey extracellular 
growth regulatory signals inside the cell and into the nucleus31.  The GLI and SMO 
proteins are likewise primary pathway proteins and mediators of critical functions in the 
HHP.  Each cell type will also have a variety of cell-specific transcription factors, which 
mediate a plethora of different HHP responses.  These cell-specific transcription factors 
include those that upregulate some of the proteins involved in tumorigenesis: Vascular 
Endothelial Growth Factor, D-type cyclins which result in cell proliferation, anti-
apoptotic proteins like the B-cell lymphoma 2, and angiopoietins and other angiogenesis 
regulators.  It is no surprise that dysregulation of the HHP leads to wide spectrum of 
cancers12. 
 The HHP is critical for embryogenesis and controls cell proliferation and the 
development of the nervous system, specifically the formation of the neural tube64.  In 
regions of epithelial mesenchyme—tissue that is specific to the developing embryo and 
eventually forms connective tissue and skeletal tissue—the HHP governs the 
development of specialized organs like skin and teeth, and establishes cell boundaries4.  
These are critical steps for a developing embryo and are necessary for proper organ 
development.  Inhibition of the HHP during embryogenesis is lethal. 
 The GLIA transcription factors mediate their outcomes in specific tissues and 
specific regions during the process of embryogenesis.  GLI2A is critical for the 
development of skeletal muscle and severe skeletal abnormalities are seen with mutated 
GLI2A61.  GLI2A is more important in the development of the spinal cord and the lungs 
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than GLI1A.  The GLI factors regulate the development of the same general regions 
across all mammals during development. 
 The HHP also functions in post-developmental roles.  The HHP regulates the 
homeostasis of adult epithelial tissue39.  The epithelial skin tissues undergo a continuous 
cycle of replacement and repair.  The HHP is responsible for maintaining the stem cell 
population of the epithelial basal layer of cells, which largely regulate these cycles13.  The 
epithelial tissue that line the gut are continuously sloughed off and regenerated, and the 
maintenance and proliferation of these tissues are regulated by HHP signaling65.  The 
HHP also controls the development of hair follicles and sebaceous glands, which begin as 
epithelial invaginations into the dermis during development and whose stem cells remain 
in the epidermal basal layer; as is the case with basal layer cells, hair stem cells rapidly 
divide and differentiate into the keratinocytes of the layer of above32,41.  Epithelial tissue 
often needs to be repaired because it has been damaged, and these tissues are able to 
reactivate the HHP to help mediate wound-healing13.  The HHP in adults also restrains 
the growth of tissues in portions of the nervous system, and maintains the populations of 
neural progenitor cells61. 
Mutations in the pathway 
There are three proposed models used to describe the oncogenic activity of the HHP, but 
only the type I model is seen in BCC12,13.  Type I cancer—known also as the ligand-
independent cancer—does not depend on SHH ligand-binding but rather on HHP-
activating mutations.  Treatments for type I cancer have no effect when targeting 
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components upstream of HHP-activation mutations, or when used as SHH ligand 
blockers at the level of PTCH112. 
 Mutations in HHP genes result most often from UVR from sunlight.  These 
mutations in the pathway genes may result in gene products with altered functions, and 
these altered proteins account for the development and progression of BCC.  The primary 
drivers of the pathologic HHP activation seen in BCC are the proteins localized to the 
PC, which promote aberrant HHP signaling as a result of pathway-activating mutations13.  
The constitutive activation of the HHP resulting from these mutated proteins causes 
multiple types of epithelial basal layer cells to proliferate rapidly, fueling the 
tumorigenesis seen in BCC66.  The major genetic components involved in the 
pathogenesis of BCC are PTCH1, SMO and tumor suppressor protein p53 (p53), 
although there are many other gene products involved in the genesis and progression of 
BCC67.  Mutations on the Patched 1 gene and on the Smoothened gene may lead to a 
PTCH1 protein with loss of function mutation or a SMO protein with a gain of function 
mutation.  The dysregulation in signaling resulting from these mutations causes an 
increase in SMO activity or a decrease in PTCH1 activity that results in the hyper-
proliferation of basal cells seen in BCC22,24.  This uncontrolled cell proliferation forms 
the tumors or lesions detrimental in mBCC.  The reduction of these tumors is the goal of 
treatment for mBCC. 
 Proteins like PTCH1 and SMO that localize to the PC feature a signal sequence 
that directs them to the rough endoplasmic reticulum for translation.  Here they are built 
into segments of the plasma membrane and packaged into a vesicle, which buds out into 
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the cytoplasm.  This vesicle easily integrates into or out from the plasma membrane of 
the PC as directed.  If a mutation occurs in the section of the gene that codes for the 
signal sequence of the cytoplasmic tail of one of these proteins, there may be a reduced 
ability of the protein to localize to the PC. 
 The most common site of mutation in the HHP is on the Patched gene22,26, and 90 
percent of BCCs have mutations here66, which result in a loss function in the PTCH1 
protein32.  A nonsense mutation (CAG > TAG) in exon 2 creates a premature STOP 
codon (pQ84), and causes the translation of a truncated protein with loss of function to 
inhibit SMO68.  Deletion mutations also result in translated proteins with truncated 
length.  Deletions affecting the cytoplasmic tail of PTCH1 can result in increased SMO 
activity61.  The W844C mutation in PTCH1 upregulates expression of HHP genes and 
gives support to the idea that mBCC is driven by hyperactivation of the HHP69. 
 PTCH1 inactivation and/or SMO activation increase GLI2A and GLI3A, the active 
forms of the GLI transcription factors.  These transcription factors effect an increase in 
the proteins involved in the HHP.  With increased oncogenic activity in BCC these 
proteins regulate positive or negative feedback systems of the HHP.  For example: a 
decrease in PTCH1 causes an increase in SMO-initiated gene transcription, the translated 
proteins of which are additional SMO proteins, which cause an increase in SMO-initiated 
gene transcription.   
 The mutations that decrease the signaling function of the SHH ligand are seen at 
its N terminus.  The mutations that affect its intramolecular processing are seen at the C-
terminal domain of the protein41. 
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 The gene product of tumor suppressor gene p53 is the tumor suppressor protein 
p53, a key regulatory protein of the cell cycle70.  The cell cycle refers to the stages of cell 
division that a cell cycles through, and has four phases: 1) G1, which is normal cell 
function 2) S-phase, in which a cell replicates its genomic material 3) G2, in which a 
somatic cell prepares for mitotic division, and 4) M-phase, in which the cell divides.  The 
G1-S checkpoint lies between G1 and S-phase and is where p53 prevents heavily mutated 
cells from continuing on into the S-phase to replicate their DNA.  Mutations to tumor 
suppressor gene p53 are involved in the progression of BCC and appear in over 50 
percent of BCC cases9.  There is a high frequency in p53 mutations present in many other 
cancers and so p53 is not directly connected or specific to the HHP/BCC. 
HHP therapeutics at the molecular level 
Pathway modulators target components upstream of SMO.  Robotnikinin is a small 
molecule that binds the extracellular SHH protein and prevents it from binding to 
PTCH113.  SHH pathway signaling can be resumed with use of a SMO agonist, because 
SMO acts directly downstream of the SHH receptor PTCH171.  HH antibodies bind 
PTCH1 and interfere with HH ligand and receptor binding.  CA1 and CA2 are two 
inhibitors of the HHP which inhibit cilia biogenesis35.  A HH-directed acyltransferase 
enzyme is required for proper HH ligand-receptor binding.  A compound called RU-SKI 
interferes with the acetyltransferase and blocks HHP signaling72. 
 Hedgehog pathway inhibitors (HPIs) are drugs, antibodies or proteins that are 
given to animals or cells and which inhibit HHP signaling12.  HPIs act at the level of 
SMO or downstream of SMO when used to treat aberrant HHP signaling in type I ligand-
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independent cancers.  Blocking the SHH ligand from binding PTCH1 will not be 
effective because it is the mutation of key pathway proteins—and not ligand binding—
which mediate aberrant HHP signaling12.  Two commonly used types of HPI are the 
small-molecule inhibitor (SMI) and the small-molecule activator (SMA).  The SMIs often 
target the HHP at the plasma membrane of the PC, and have a high binding-affinity for 
the extracellular DBP of SMO—a specific location on the extracellular surface of the 
protein where a drug binds its receptor.  These SMO SMIs (SMOSMI) are the key 
regulators of aberrant type I pathway signaling and this work will further discuss the 
mechanism of action of three SMOSMI which inhibit aberrant HHP activity.  These bind 
and directly inhibit the SMO signaling cascade predominantly responsible for the 
amplification of HHP signaling.  Other types of SMO modulators can regulate the ciliary 
localization of SMO, activating or inhibiting the ciliary translocation of SMO. 
 HPIs are currently being developed that target signaling components downstream 
of SMO.  Mutations at the level of PTCH1, SMO or SUFU all result in the increased 
expression of GLI132.  Pathway-activating mutations downstream of SMO include 
inactivation of SUFU which is mutated in a small percentage of BCC cases, and more 
rarely the amplification of GLI1, neither of which will respond to SMOSMIs12.  Pathway 
modulators, which inhibit the GLI family of transcription factors, also bypass mutations 
upstream of SMO.  One such modulator is arsenic trioxide (ATO), which is used in 
combination therapy with Itraconazole.  GANT61 is a compound that inhibits GLI1A and 
inhibits GLI2A to a lesser degree12,66.  Currently, there is no clinical data about the 
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potency or specificity of GANT61 in treatment of mBCC66, but the compound has shown 
promising anti-tumor effect in multiple tumor types in preclinical studies46,73. 
 There are treatments for aberrant HHP activation from ligand-independent (type I) 
BCC progressed to mBCC.  HPIs used to treat type I cancer are SMI that work at the 
level of SMO.  There are currently seven SMOSMIs, five of which are in clinical trials 
(including Itraconazole) and two of which, Vismodegib and Sonidegib, are already in use 
as an approved treatment for mBCC.  Vismodegib and Sonidegib both act as ligands and 
bind the same DBP of SMO74.  Although they act on the same target protein in the same 
DBP they do not bind SMO at the same amino acid residues. 
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MUTATIONS IN SMO 
 
The efficacy of a SMI is dependent on its ability to bind and inhibit SMO.  Vismodegib 
and Sonidegib are two SMIs that have a specific conformation.  When effectively used as 
treatments, the SMIs are able to bind to the extracellular DBP of the SMO protein.  The 
degree of this binding-affinity corresponds to the degree of the inhibition of SMO to 
initiate the intracellular signal cascade, which causes the activation and nuclear 
localization of GLI2A and GLI3A.  The ability of a SMI to bind and inhibit SMO is 
greatly reduced when the protein carries a mutation in the DBP where the SMI acts as a 
ligand.  A mutation causes a conformational change in the binding site such that the 
ability of the SMI to bind to the DBP of SMO is greatly reduced.  When its ability to 
bind—known as its binding-affinity—is reduced, this results in a diminished therapeutic 
effect of the SMI in the patients harboring the SMO mutation66,68. 
The DBP of SMO 
SMO mutations alter the conformation of the DBP of SMO and decrease the binding-
affinity of SMO inhibitors by rendering the active site less accessible to ligand binding.  
A point mutation occurs in SMO at position 497, where the amino acid glycine is 
changed to the amino acid tryptophan (G497W)66,68.  G497W prevents binding of SMO 
inhibitors to the DBP in the extracellular region of the protein75, which prevents drug-
mediated inhibition of SMO signaling.  The presence of this mutation resulted in disease 
progression in an mBCC patient treated with Vismodegib, whose tissue biopsy showed a 
continuous rate of tumor growth.  The patient was administered Vismodegib treatment 
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for 60 days, but the effect was the same as if treatment had not been administered 
because the SMI could not bind the active site of the mutated SMO-G479W.  A point 
mutation also occurs in SMO at position 477, where the aspartic acid is changed to the 
amino acid glycine (SMO-D477G)76.  This mutation represents an acquired resistance 
which blocks the therapeutic effect of both Vismodegib and Sonidegib in mBCC 
treatment35,74,77. 
 Because cells cultured in vitro can be transfected to express proteins carrying 
defined mutations, these cells can be used to determine the degree to which any given 
SMO mutation is blocking SMI function.  Transfected cells were treated with SMIs, and 
the resulting growth of the culture was measured to define the importance of the SMO 
mutation in the HHP.  The residues at position 281, 469, and 518 likely mediate binding 
to Vismodegib78.  SMO proteins with the mutations SMO-W281C and SMO-C469Y 
were expressed in cells and treated with Vismodegib.  Cell proliferation resulting from 
activated SMO can be fully inhibited with the administration of 100 nM of Vismodegib.  
The cell proliferation rates seen with activating mutations SMO-W281C and SMO-
C469Y were unchanged with the administration of Vismodegib, and cells continued to 
proliferate at near untreated levels, even with the administration of 5000 nM of 
Vismodegib78.  This strongly suggests that these two residues are part of the binding site 
for Vismodegib in the DBP of wild-type SMO (SMO-WT)—the protein with no 
mutation.  Similar studies implicated a SMO mutation at position 518 as a critical residue 
in the DBP.  The SMO-E518K mutation blocks binding of Vismodegib to the SMO 
DBP76. 
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 Several SMO mutations inhibit the therapeutic effect of the SMI Sonidegib.  The 
most common activating mutation in SMO12 is the point mutation SMO-W535L, an 
oncogenic mutation that diminishes the ability of PTCH1 to inhibit SMO.  The SMO-
W535L mutation causes a conformational change to SMO, which inhibits Sonidegib from 
accessing the DBP74.  Another known oncogenic mutation is SMO-S533N, a mutation 
outside the DBP that likely causes a conformational change that renders the DBP of SMO 
inaccessible for Sonidegib79.  Other SMO mutations known to block Sonidegib action are 
S391N, G457S, D388N, N223D, and L225R.  The D473 and Q476 residues in the SMO-
WT are known to be part of the DBP of Sonidegib.  Mutations occur in both of these 
positions and prevent Sonidegib from binding the DBP of SMO79.  Position 473 is on the 
extracellular lip of the central cavity of the SMO DBP. 
SMIs and binding-affinity 
A gain of function mutation in the SMO protein is common in BCC, and seen in about 
10-20 percent of cases9,22,66.  The majority of cases of resistance to treatment come from 
SMO mutations78.  There are two general classes of SMO mutations: Those in the drug-
binding pocket (DBP) and those outside the DBP.  Mutations affecting the DBP are more 
severe and prevent the SMI from being able to bind by changing the amino acids required 
for SMI binding at the DBP.  Mutations distal to the DBP are less severe and reduce the 
binding-affinity of the SMI for the DBP by changing the conformation of the DBP and 
reducing the ability of a SMI to enter the DBP and bind the protein. 
 The physical presence of the appropriate amino acid residues is a prerequisite for 
binding in the DBP.  The chemical interactions between the SMI and its compatible 
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residues in the DBP of SMO are critical for interaction with SMO.  The amino acid 
residues comprising the DBP are able to bind the SMIs of SMO.  The DBP of SMO 
features a number of extracellular extensions, small protrusions of regions of SMO, 
which interact with potential ligands.  These extensions are from the extracellular tips of 
alpha helices of the SMO protein, secondary protein structures capable of interacting with 
the SMIs that bind SMO.  The DBP of SMO contains three important residues: D473, 
R400, and E51874.  R and E are basic and acidic amino acids, respectively, which are a 
category of amino acid commonly seen in the active sites of cell surface proteins.  The 
R400 residue in the DBP is at the tip of the one of the protruding alpha helixes, and binds 
the phthalazine ring of Sonidegib74. 
 The strength of the binding-affinity of SMIs is modulated by at least three 
features of the DBP, listed in decreasing order of importance: The physical presence of 
the appropriate amino acid residues, uninhibited entry into the drug binding site, and full 
binding access free from impediments of other ligands at the DBP. 
 Additional mutations in the DBP include: SMO-W281, SMO-V321, SMO-C469, 
SMO-N219, and SMO-D384.  Mutations located at positions in the SMO DBP are often 
severe and show resistance to SMO inhibitors.  SMO-WT requires 1 unit of SMO 
inhibitor treatment to have a 50 percent effect, but SMO mutations with resistance to 
SMO inhibitors require 12 to 50 units of SMO inhibitor to have a 50 percent effect78.  
The (SMO-W281C) mutation requires the highest dose of Vismodegib to show any 
effect.  It is 10,000 times less likely to be bound in the DBP by Vismodegib than SMO-
WT78.  SMO-W281 and SMO-C469 likely directly bind to SMO inhibitors in the DBP, 
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because both SMO mutations cause cell proliferation at rates similar to untreated cells 
even after doses 50 times higher than the dose needed to halt cell proliferation stimulated 
by SMO-WT78. 
 Mutations outside the DBP include: SMO-T241M, SMO-A459V, SMO-W535L 
and SMO-G497W.  SMO-G497W obstructs the access of a SMI to the SMO DBP68.  The 
substituted tryptophan is the largest amino acid, and its bulk contributes to a 
conformational change, which narrows the size of the opening to the DBP of SMO.  This 
results in a moderate but direct reduction in protein binding-affinity for the SMO 
inhibitor, as would be expected with a non-DBP mutation68.  SMO mutations that are 
distal to the DBP destabilize the SMO structure, which promote SMO activation and 
reduce SMO sensitivity to SMO inhibitors78.  SMO-WT requires 1 unit of SMO inhibitor 
treatment to have a 50 percent effect.  Mutations affecting non-DBP regions of SMO 
require 3 units (SMO-T241M) to 9 units (SMO-A459V) of SMO inhibitor treatment to 
have a 50 percent effect78. 
Mutations at position 473 
An aspartic acid residue is found in SMO at position 473, one of the most important 
positions in the SMO DBP.  The amino acid residue at this position is on the extracellular 
lip of the central cavity which encircles the SMO DBP75.  The amino acid residue at this 
position can undergo a mutation to SMO-D473X, where X represents any other amino 
acid.  SMO resistance to SMOSMIs arising from mutations at position 473 at the DBP of 
SMO are a concern for the future use and efficacy of both Vismodegib and Sonidegib but 
are also an example of mutations that alter the binding-affinity of a drug35,74,75.  These 
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mutations have revealed several important effects of SMO mutations on single ligand 
binding-affinity, multiple ligand binding affinities, binding locations and binding 
outcomes35,46,68,69,74,75,77,78,80. 
 When SMO D473 is mutated and the aspartic acid is substituted with any other 
amino acid (with the exception of the amino acid proline), the two resulting effects are: 
SMO will retain its functionality, and SMO will have reduced sensitivity to 
Vismodegib76.  These effects show that mutations in SMO at position 473 are not 
essential for SMO activity, and more importantly that position 473 is essential for 
Vismodegib binding.  Almost all mutations resulted in a reduction in the binding-affinity 
of Vismodegib for the DBP of SMO, and a reduction in the efficacy of Vismodegib 
treatment as a SMO inhibitor69.  
 A common mechanism of drug resistance occurs when the change of a single 
amino acid residue causes a deficiency in the binding-affinity of a drug for the DBP of its 
target protein.  The strength of the binding-affinity of Vismodegib for the DBP of SMO is 
determined by the residue at position 473.  The amino acid X, which replaces the aspartic 
acid in the mutated SMO-D473X, determines the strength of the effect.  Different amino 
acids reduce the ability of Vismodegib binding to a different degree.  SMO-WT shows a 
50 percent inhibition of activity when treated with one unit of Vismodegib.  When the 
aspartic acid at this residue is replaced with a glycine, SMO-D473G shows a 50 percent 
inhibition of activity when treated with one hundred units of Vismodegib.  The SMO-
D473G protein is inhibited to a greater degree when treated with the SMI Itraconazole, 
and is fully inhibited when treated with a combination of Itraconazole/ATO81.  When the 
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aspartic acid at this position is replaced with a histidine, SMO-D473H shows no 
inhibition of activity, even when treated with 150 units of Vismodegib75.  The greatest 
reduction in Vismodegib binding-affinity for the SMO DBP occurs when the charged 
acidic residue at position 473 is replaced with a basic residue having an opposing charge. 
 SMO-D473H is a missense mutation that was first detected in a patient with 
mBCC who initially showed a positive response to Vismodegib treatment, followed by 
progression of the disease caused by the SMO mutation76.  This mutation was the first 
recorded occurrence of clinically acquired resistance to Vismodegib and resulted in rapid 
progression of disease and tumor growth8.  Both SMO-WT and SMO-D473H have 
similar activity at the level of signal transduction and signaling at which both SMO 
proteins are intact; both proteins also are inhibited by PTCH175.  Unlike the SMO-WT 
protein, SMO-D473H is refractory to inhibition by Vismodegib23,69.  Vismodegib is able 
to bind at the DBP of SMO-WT but is unable to bind at the DBP of SMO-D473H75.  The 
SMO-D473H mutation changes the conformation of the opening to the DBP, which 
prevents Vismodegib from access to the active site of SMO35,75.  Vismodegib is spatially 
inhibited from accessing the DBP in SMO69.  This loss of sensitivity to Vismodegib also 
results from a mutation at position 473 to positively charged amino acids: R or K.  SMO-
D473R and SMO-D473K show auto-activating properties and are resistant to PTCH1 
inhibition76. 
 The mutation of a single residue in the DBP can inhibit the binding the multiple 
SMOSMIs.  When position 473 is mutated such that the amino acid is replaced with the 
bulky tyrosine amino acid, the binding affinities of multiple SMIs are reduced.  The 
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SMO-D473Y mutation changes the conformation of the SMO protein at the extracellular 
region of the protein, which lines the DBP in such a way that access to the active site is 
impeded and Vismodegib binding to the DBP of SMO is decreased by multiple orders of 
magnitude23,68,82.  The mutation has a similar effect on the binding-affinity of Sonidegib.  
Point mutations in the DBP of SMO that introduce a large, bulky amino acid are more 
likely to reduce binding of multiple SMIs than mutations that introduce smaller amino 
acids. 
 These mutations happen within the context of the ciliary trafficking of SMO, and 
within the pathway interactions that cause the activation and inhibition of SMO.  The 
nature of the mechanisms that direct these processes are still unclear, but the discovery of 
the mechanisms of action underlying these processes is likely to increase and diversify 
the treatment options for patients with SMO resistant mutations35,37. 
Goals:  
This work will discuss the SMI therapeutics currently used to treat mBCC.  It will also 
compare the treatment outcomes across clinical trials for Vismodegib and Sonidegib, to 
determine which treatment is the best option for patients with mBCC, with respect to 
clinical outcomes and drug side-effect profiles.  Finally, it will examine 
Itraconazole/ATO, a combinatorial therapeutic currently under investigation, as a 
potential treatment for mBCC.  Specifically, this work will: 
1.  Review treatment options for mBCC with mutations in the HHP. 
2.  Compare drug-based treatments for mBCC to assess optimal treatment outcomes. 
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RESULTS 
mBCC drug-based treatment options 
Treatments are available for each type of BCC and the type of treatment required depends 
on the stage of cancer.  Non-metastatic BCC is generally treated with one of two 
methods, dependent upon the size and location of the BCC tumors.  Surgery is the 
treatment of choice for small tumors in a low-risk epithelial location.  Surgical excision 
of BCC has a high success rate and minimal complications.  For recurrent tumors, or 
wider tumors in more anatomically challenging epithelial locations, the suggested 
treatment is with Mohs micrographic surgery66.  A wider diameter tumor seen in a case of 
laBCC can be treated dependent upon the cancer staging, and treatments may employ 
surgery, radiotherapy or pharmaceutics66,83. 
 There is a high prevalence of dysregulation of the HHP in mBCC, which is 
treated with the use of therapeutic drugs and cannot be treated with excisional surgeries.  
The only available treatments are SMO antagonists, which bind at the DBP of SMO and 
prevent pathway signaling from SMO to downstream targets.  The treatment modalities 
for mBCC are drug-based, employing medications—Vismodegib, Sonidegib, and 
Itraconazole/ATO—that target the HHP (implicated in a majority of mBCC cases) and 
which are the only prescribed treatment for end stage mBCC.  Vismodegib and Sonidegib 
are SMOSMIs that have many data points associated with their use in treatment—from 
both clinical research and therapeutic trials.  Itraconazole/ATO is a promising drug 
candidate for use in combination therapy with Vismodegib or Sonidegib as a treatment 
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option for patients who have SMO mutations that are refractory to Vismodegib or 
Sonidegib. 
 The therapeutics are specific for the HHP and are not used as a treatment for other 
signaling pathways.  HPIs act at the level of SMO while ATO acts downstream of SMO 
at the level of GLI2, and these treatment options are commonly used and have good 
clinical outcomes for type I, ligand-independent mBCC.  Clinical trials were conducted 
for patients with aBCC—most often mBCC although sometimes laBCC patients were 
involved in trials, as noted—with histologically confirmed advanced dysregulation of 
HHP activity. 
Mechanism of action 
Vismodegib 
Physiologic HHP signaling is activated when the lipid modified N-terminal domain of the 
SHH ligand binds PTCH1 localized at plasma membrane at the base PC.  This results in 
the transport and degradation of PTCH1 and the subsequent activation and ciliary 
localization of SMO.  The SMO signaling cascade modifies the activity of a number of 
downstream proteins whose interactions effect the activator state of GLI-family 
transcription factors, which bind and induce the transcription of HHP genes.   
 Activation of pathologic HHP signaling is often seen with a loss of function 
mutation to PTCH1, or gain of function mutation directly downstream in SMO.  Either 
mutation can be effectively treated with HPIs at the level of SMO, except in cases where 
the mutation affects the binding-affinity of the SMI for the extracellular binding pocket 
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of SMO.  An activating mutation in SMO ultimately increases the transcription of HHP 
target genes, whose protein products fuel the initiation and acceleration of BCC.  SMO-
WT and to lesser degree mutated SMO can be bound by Vismodegib, a SMI with a 
specific binding-affinity for the DBP of SMO.  Administration of the pharmaceutic drug 
inhibits the SMO-mediated transduction of physiologic HHP signaling, and reduces the 
level of signaling activity seen with aberrant pathologic activation of the HHP84.  Once 
bound to SMO, Vismodegib mediates the inhibition of SMO signaling irrespective of the 
binding of SHH ligand to PTCH1.  Vismodegib-mediated inhibition of SMO also occurs 
irrespective of whether PTCH1 has a loss of function mutation or is in its wild-type 
conformation67,84.  Vismodegib is thus an effective antineoplastic treatment for mBCC in 
adults with dysregulated HHP signaling resulting from pathway-activating mutations in 
HHP proteins85. 
 The end effect of Vismodegib treatment is the inhibition of SMO, which prevents 
GLI1A, GLI2A and GLI3A transcription factors from nuclear localization and binding to 
HHP genes, preventing their transcription and translation, and reducing the production of 
HHP proteins.  The measured levels of GLI1A are highly correlated with the activity of 
the HHP, as GLI1A exists only as an activator transcription factor and has no repressor 
form55.  The measurement of cellular levels of mRNA transcripts for GLI1 provide 
quantitative evidence that Vismodegib is an effective treatment for mBCC.  The 
measured level of GLI1 in the tumor biopsies of mBCC patients treated with Vismodegib 
is lower than the GLI1 levels from the same tumor biopsies recorded before the onset of 
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treatment13.  Vismodegib is a mBCC therapeutic with a proven record of successful 
treatment. 
Sonidegib 
The DBP of SMO is where SMIs of SMO often bind in the treatment of mBCC.  There 
are two SMIs of SMO used in mBCC treatment74, one of which is the therapeutic 
Sonidegib, which is also indicated for treatment of laBCC where complications prevent 
radiotherapy as a form of treatment74,83.  The DBP of SMO, also referred to as its active 
site, is a region on the extracellular surface of the protein, which can be bound by a 
ligand.  When SMO is bound by the ligand Sonidegib, a SMI that targets the same DBP 
as Vismodegib, the seven-transmembrane domain protein is inhibited.  There is no 
activation of SMO and no subsequent signal transduction and signal amplification of 
SMO as a result86,87.  When SMO is inhibited it cannot transduce HHP signaling to 
intracellular proteins.  GLI2 and GLI3 are sequentially 1) sequestered in the cytoplasm by 
SUFU, 2) phosphorylated by a triad of kinases, 3) truncated by a protease to GLI2R and 
GLI3R, 4) localized to the nucleus, 5) bind the DNA regulatory regions of HHP targets 
and 6) repress the transcription and translation of HHP target genes.  Without gene 
transcription, the amount of mRNA transcripts coding for HHP products, including GLI-
family transcription factors, remains unchanged.  HHP gene products code for the 
intracellular, extracellular and membrane proteins, which mediate much of the activity of 
aberrant HHP activity in mBCC.  Pathway genes are not transcribed, pathway proteins 
are not produced, and there is no increase in the activity of the HHP86,87.  The direct 
effects mediated through inhibited HHP activity are decreases in the cell proliferation in 
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mBCC.  This corresponds to the quantitatively measurable histologic reduction in the size 
of mBCC lesions, and to patients in clinical trials reaching qualitatively measurable 
responses88. 
Itraconazole/ATO 
Itraconazole is another HPI used in the treatment of mBCC.  The binding site of 
Itraconazole is undetermined, although it is known to bind downstream and 
independently of PTCH189.  Several hypotheses are currently suggested for the 
mechanism of binding for Itraconazole. 
 The most widely accepted hypothesis for binding is that Itraconazole is an inverse 
agonist of SMO89, that is, it binds and stabilizes SMO in its inactive conformation90.  
Unlike the other SMOSMIs, Itraconazole does not appear to bind the DBP of SMO.  If 
this is the case, then Itraconazole likely binds SMO at an allosteric site, a binding region 
on the extracellular surface of SMO, distinct from the DBP81.  When SMO is 
concurrently bound by a SMI at the DBP and by Itraconazole at an allosteric site, SMO is 
inhibited and the effect is additive.  When SMO is concurrently bound by an agonist at 
the DBP and by Itraconazole at an allosteric site, Itraconazole does not function as a 
SMO inhibitor, and SMO is activated89. 
 Other hypotheses have been suggested for Itraconazole’s mechanism of binding.  
It has been postulated that the DBP is large enough to accommodate two non-overlapping 
modulators simultaneously.  If this is the case, and if the two molecules are the correct 
shape and size, Itraconazole may bind concurrently with Vismodegib or Sonidegib in the 
DBP81.  Less likely, Itraconazole may act as an allosteric inhibitor of another molecule, 
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perhaps the previously referenced endogenous SMO agonist, to affect the ciliary 
accumulation of SMO. 
 The location where the ligand binds to the extracellular region of SMO is unclear, 
but the mechanism of Itraconazole’s function is known to inhibit the translocation of the 
protein to the PC89.  When SHH binds to PTCH1 there is an increase in the ciliary 
accumulation of SMO, and the measured proportion of primary cilia containing SMO is 
90 percent.  When this identical process happens concurrent with the administration of 
Itraconazole, the measured proportion of primary cilia which contain SMO drops from 90 
percent to 5 percent89.  The mechanism of SMO localization remains unclear but the 
physical trafficking of the protein is likely directed by the basal body of the PC. 
 ATO is a highly versatile GLI antagonist and a potent HPI.  In contrast to SMO 
SMIs, which only target SMO and only work in type I treatment, ATO acts farther 
downstream and has effect where SMO inhibitors do not, including pathway activity 
resulting from: mutations downstream of SMO, increased GLI activity, and most 
importantly SMO mutations, including those resistant to SMIs.  ATO treats all three 
cancer types, and efficiently reduced HHP activity in trials90.  The concentrations of ATO 
required in vitro for inhibition of HHP activity are already used in human treatment for 
other maladies90. 
 ATO acts within the HHP at a level downstream of SMO and SUFU.  
Constitutively active SMO signaling can be suppressed with the administration of ATO90.  
GLI2 trafficking in and out of the PC is necessary for GLI2 activation to GLI2A.  ATO 
inhibits the ciliary accumulation of GLI2, but not of SMO, which results in inhibition of 
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GLI2 activation to GLI2A46,90.  The GLI2 levels in the PC drop with long-term ATO 
treatment; this effect could be mediated by increased proteasomal degradation into 
GLI2R. 
 The combination therapy of ATO with Vismodegib, or ATO with Sonidegib, 
allows for stronger pathway inhibition at lower drug concentration than independent 
treatment with the SMI alone.  Between 2 and 7 units of a SMO SMI were needed for 50 
percent inhibition of the HHP, whereas only 1 unit was needed for the same effect in 
concurrent treatment with ATO and a SMO SMI90.  But the ATO/SMOSMI combination 
is not as potent as the Itraconazole/ATO combination.  The combination therapy of 
Itraconazole and ATO inhibited HHP activation and tumor growth driven by SMO 
mutations including those with acquired resistance to SMO antagonists81.  SMO-D477G, 
an acquired resistance that blocks the therapeutic effect of Sonidegib in mBCC 
treatment77, underwent in vivo testing in a mouse model, with a combination treatment 
with ATO and Itraconazole.  Over the course of nine days the treatment inhibited 100 
percent of tumor growth and caused tumor regression of almost 50 percent81. 
 The combination therapy of ATO and Itraconazole is effective for treatment of 
every reported SMO mutation81.  This therapeutic regimen simultaneously targets two 
distinct and critical locations in the HHP: the SMO and GLI proteins.  The additive 
inhibitory effect of Itraconazole/ATO treatment permits the use of lower doses of each, 
resulting in improved anti-tumor efficacy while also decreasing the experience of adverse 
side effects and other toxicities81. 
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Efficacy of various treatment options 
The effect of a treatment for mBCC can be measured in terms of the objective response 
(OR): the number of patients reaching the objective, measurable response of a tumor to 
an anticancer agent as specified by an evaluable, standardized reduction in tumor size88.  
In the context of clinical trials, the OR is used as one measure to determine how well a 
novel treatment is working and is recorded at intervals spanning from a baseline measure 
at the outset of a treatment through to the primary analysis at the end of the study88.  
There are four measured values or categories commonly used to further classify the 
measurable OR of solid tumors in response to treatment: a complete response (CR), a 
partial response (PR), stable disease, and progressive disease88.  Patients reaching an OR 
have tissue biopsies evaluated, and the quantitative measure of the exhibited tumor 
response is then sufficient to qualitatively divide all patients in the cohort into one of the 
four categories66,88.  For some studies the sum of patients showing CRs and PRs equals 
the value of the OR for the study66.  The OR is routinely evaluated by two groups: an 
independent review, and the investigator review88,91–93. 
Vismodegib 
A 2012 phase II trial of Vismodegib enrolled 33 participants with histologically verified 
mBCC.  Each participant was given a 150 mg oral dose of Vismodegib daily for 400 
days93.  The study had no control group because the patient population was small, there 
was a lack of available effective therapies, and it was not ethical to prohibit treatment for 
patients with terminal stage mBCC93. 
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 The primary endpoint for the study was an assessment of tumor activity in 
biopsies from the mBCC patients.  At this point the OR rate would be evaluated by two 
groups: An independent committee review, and the clinical researchers.  The OR for the 
study was reached if there was a decrease of 30 percent or more in the externally visible 
target lesion(s)93.  The trial’s OR rate was hypothesized to be greater than 10 percent.  
The actual OR rate, as assessed by the independent committee review, was 30 
percent83,93.  The CR for the study was reached if histological assessment of the biopsied 
tissue sample revealed no BCC. 
 By the time of the primary analysis of the study 58 percent of the mBCC patients 
were still receiving treatment66.  None of the patients reached a CR and one of the 
patients had missing data and their response to Vismodegib was not evaluated83,93, but 30 
percent of the patients reached the PR, and 64 percent83 of the patients showed evidence 
of stable disease93—meaning their mBCC had not progressed during the study’s sixteen-
week course.  73 percent of the patients with mBCC experienced tumor shrinkage as a 
result of Vismodegib treatment66, while 27 percent did not respond to treatment.  Only a 
single patient of the group experienced disease progression94, defined either as a greater 
than 20 percent increase in target lesion size, or the histologic presentation of new ulcers 
or lesions66,88.  All patients were screened prior to being accepted into the study, which 
revealed that 30 percent of the patients had undergone prior systemic therapy 
treatments93.  Retroactive analysis suggests that treatment response with Vismodegib is 
negatively associated with prior systemic therapy treatment, including those using 
Vismodegib or Sonidegib66.  Both SMIs bind the same DBP of SMO, and a mutation in 
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this region decreases the binding-affinity of either drug.  The 27 percent of enrolled 
patients not responding to treatment might have been carrying a SMO mutation as a result 
of previous treatment with a SMI of SMO.  If so, this mutation conferred the resistance to 
treatment seen in the clinical trial. 
 A year after the primary analysis a follow up analysis was conducted.  At that 
time, 21 percent of the mBCC patients were still receiving treatment with Vismodegib92.  
This clinical study confirmed that Vismodegib is an effective treatment for mBCC.  The 
follow up analysis demonstrated that the responses reached by patients during treatment 
were durable, and that Vismodegib could be administered over a prolonged period and 
provide a stable therapeutic effect continuously over the course of that time66,92. 
Sonidegib 
In one randomized, double blind phase II trial, Sonidegib was administered in two doses 
to a group of 36 patients with mBCC over the course of a year and a half91,94.  Two-thirds 
of the patients (n =23) were assigned to be orally administered 800 mg of Sonidegib a 
day, and the rest of the patients (n = 13) were assigned to be orally administered 200 mg 
of Sonidegib per day91.  No placebo was used, because this was deemed to be unethical 
for patients with mBCC.  Also, no comparative drug group was available for use as a 
control.  This trial was the first comparative study of two doses of Sonidegib, and was 
undertaken to determine the safety and antitumor profiles of Sonidegib. 
 The first assessments were recorded at baseline, at the start of the trial.  The next 
assessments were taken at week 5, after that at week 9, and then continuing every eight 
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weeks for the first year and every twelve weeks after that, until discontinuation of the 
treatment91. 
 Patients who reached the OR after six or more months of treatment reached the 
primary endpoint for the study66.  Two review groups, an independent review committee 
and an investigator review, used histological samples of multiple biopsies to further 
classify if the response of patients reaching the OR was a CR or a PR, the nature of which 
was determined by assessment of the depth, width and length of lesions and granularity88.  
A PR was given if two conditions were met: There was a greater than 30 percent decrease 
in target lesions, measured as the sum of their longest diameters, and there was at least a 
50 percent reduction in tumor size when measured as the sum of the products of 
perpendicular diameters66,88.  A CR required complete resolution of all lesions, and the 
same result when assessed again after four weeks66.  An epithelial-tissue biopsy was 
employed to measure the tumor response of each patient to treatment with Sonidegib.  
The results were used to qualify the response to treatment reached by each patient as 
either a CR or a PR.  
 The independent review put the CR at 0 for patients in either the 200 or 800 mg 
Sonidegib dose; the investigator review put the CR at 0 for the 200 mg Sonidegib, but at 
2 (9 percent) for the 800 mg Sonidegib91.  The independent review put the PR at 2 (15 
percent) for patients in the 200 mg Sonidegib dose, and at 4 (17 percent) for patients in 
the 800 mg Sonidegib dose; the investigator review put the PR at 3 (23 percent) for the 
200 mg Sonidegib dose, but at 6 (26 percent) for the 800 mg Sonidegib dose91.  Both 
disease control and tumor shrinkage were observed in 92 percent of the mBCC patients66. 
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 These clinical findings helped demonstrate the safety and efficacy of Sonidegib as 
a treatment for mBCC.  The comparison of treatment outcomes and side effects across 
the two dosing groups showed that a higher dose was not correlated with a better 
treatment outcome74,91, and that patients administered lower doses of Sonidegib 
demonstrated a better benefit-risk profile than patients administered higher doses66. 
 A subsequent follow up to the study was taken, and this 12-month analysis was 
also evaluated by an independent review committee and an investigator review.  The OR 
was reached by 8 percent and 23 percent in the 200 mg group, by independent review and 
investigator review, respectively.  The OR was reached by 17 percent and 35 percent in 
the 800 mg group, by independent review and investigator review, respectively.  
Independent review determined that disease control was reached by 91 percent and 92 
percent in the 200 mg group and 800 mg group, respectively; additionally, independent 
review determined that tumor shrinkage by any modality was reached by 92 percent and 
84 percent in the 200 mg group and 800 mg group, respectively86.  These results showed 
that the long term administration of Sonidegib continued to demonstrate a meaningful 
response in the reduction of tumors66, and maintained extended efficacy as a treatment for 
aBCC74,86,91. 
 Sonidegib is not effective when used in patients who have had previous systemic 
therapy treatments with Vismodegib74.  This effect is also seen in Vismodegib.  Clinical 
findings demonstrate that the majority of patients who switch to treatment with Sonidegib 
following resistance to Vismodegib experience disease progression74.  An open-label 
study assessed the tumor response to Sonidegib in patients with aBCC that was 
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previously resistant to Vismodegib treatment.  The clinical characteristics and treatment 
outcomes of nine patients with Vismodegib-resistant aBCC were assessed when treated 
with Sonidegib.  The outcomes showed that disease progression and tumor growth 
continued when treatment with one SMI was replaced by treatment with the other SMI.  
The results demonstrated that patients with aBCC resistant to treatment with Vismodegib 
were also refractory to treatment with Sonidegib, due to SMO mutations which prevented 
the antagonist effects of SMOSMIs74,79. 
Itraconazole/ATO 
In one small, exploratory phase II trial, Itraconazole was found to reduce patients’ tumor 
size by 25 percent (none were entirely eliminated)95,96.  21 percent of patients reached 
stable disease—used to describe a tumor which does not grow, shrink or metastasize—or 
a PR66.  Current and planned trials are exploring the efficacy of the drug in combination 
with other HPIs, as targeting two points along the pathway, may provide a more 
comprehensive and effective treatment option.  Itraconazole can be used as a treatment 
when patients experience resistance to treatment with Vismodegib or Sonidegib because 
of SMO mutations.  Researchers found in 2013 that Itraconazole was more effective 
when administered alongside the cancer drug ATO81, a HPI which inhibits activation of 
the GLI2 transcription factor downstream of SMO.  ATO works by preventing ciliary 
trafficking and destabilizing GLI2, and has potential for use in combination therapy with 
Itraconazole for patients with Vismodegib-resistant mBCC95. 
 In the mouse model, Itraconazole-treated tumors show decreased activity and 
decreased GLI1 mRNA transcript levels.  The mRNA transcript levels of GLI1 strongly 
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correlate with HHP activation, therefore the reduced GLI mRNA levels in Itraconazole-
treated BCC tissue indicate its efficacy as a HPI89.  When treated with Itraconazole, BCC 
tumor growth rate is decreased compared to growth rates in the control group; after 
treatment with Itraconazole was stopped, tumor growth resumed at the same rate as in the 
control group. 
 The serum concentration at which Itraconazole is effective in treatment of 
medulloblastomas in vivo in the mouse model is the same as the serum concentration of 
Itraconazole administered in humans for antifungal treatment89.  Itraconazole 
concentrations administered for antitumor activity in human patients may need to exceed 
the concentrations administered for antifungal activity however, because dosage is at 
higher levels to treat cancer than to treat fungal infections.  Further studies are needed to 
determine the dosage, the side effects, and the long-term effects of Itraconazole use as a 
cancer treatment, but the drug remains a promising candidate for a therapeutic compound 
that could be used in combination therapy for mBCC treatment. 
Adverse events 
Treatment for mBCC is often effective, but the undesirable side effects may preclude 
their use in some—or all—patient populations. Each of the described mBCC drugs has 
been shown to induce side effects ranging from mild to serious. 
 All targeted therapeutic drugs that work as HPIs are contraindicated in pregnant 
populations.  The HHP is integral in fetal development and SMO inhibitors such as 
Vismodegib, Sonidegib and Itraconazole are therefore harmful or fatal to the fetus9.  
Further clinical research is needed to determine whether HPIs can be indicated for use in 
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(rare) cases of mBCC in the pediatric population.  Permanent damage to bone structure 
has been seen upon short-term administration of HPIs in vivo in developing mice.  More 
preclinical research is needed to assess the possible spectrum of risks associated with the 
use of HPIs in pediatric populations12.  In adults the HHP is physiologically active in the 
regeneration or growth of skin or hair follicles9 and in maintaining the stem cells of the 
epithelial basal layer.  All SMIs of SMO are safely indicated for adult treatment of 
mBCC, because the arrest of HHP signaling in these post-embryonic roles is not life 
threatening67,84,85. 
Vismodegib 
In the 2012 phase II trial, nearly a third of the enrolled patients (ten of 33) reported 
adverse events (AE)66,83,93.  These included alopecia (hair loss), weight loss, fatigue, 
muscle spasms, and dysgeusia (loss of the sense of taste)94.  Another trial (in which 12 
percent of the patients experienced toxicity and withdrew from the study) recorded all of 
the above and anorexia83.  The most commonly experienced adverse events, experienced 
by at least 20 percent of all patients, were: muscle spasms, decreased weight, decreased 
appetite, dysgeusia, nausea, diarrhea, alopecia and fatigue93. 
 In one study, 25 percent of the patients died during treatment83,94.  Three of the 
deaths were attributed to an unknown cause.  Four of the deaths were attributable to a 
known cause.  One patient died from hypovolemic shock, one from a heart attack, one 
from meningeal disease, and one from a stroke83.  Atrial fibrillation and hyponatremia 
have also been recorded in other clinical trials with Vismodegib13.  All seven of the 
patients had comorbidities or additional risk factors. 
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 Vismodegib showed generally good short term results in its first few years, but 
the side effects of the drug proved intolerable to many patients, as shown by the high 
patient dropout rate, up to 42 percent in one trial93,96.  Although Vismodegib and 
Sonidegib share similar safety profiles, the side effects experienced by patients taking 
Vismodegib seem to be more severe than those experienced by the patients taking 
Sonidegib74. 
Sonidegib 
In the Sonidegib trial, more AEs were experienced in the 800 mg Sonidegib group than 
the 200 mg group66,74,79,83,86,91.  The most frequent AE was increased concentrations of 
plasma creatine kinase (CK).  CK is produced when skeletal muscle contracts, and 
skeletal muscle spasms are frequently reported AEs of Sonidegib administration66,91.  
Elevated CK concentrations can be a serious AE, and it is more often seen in Asian 
populations than Western populations, leading to lower dose administrations of 
Sonidegib in these populations74.  With a Sonidegib dose four times higher than that 
administered to the other group, the 800 mg group had almost 100 patients (67 percent of 
the group) who requested dose reductions, or dose interruptions.  This was four times 
higher than the number of dose reductions requested by the 200 mg group91. 
 A greater percentage of patients in the high dose group chose to discontinue the 
treatment than in the low dose group.  The 800 mg group had 36 percent of patients (n = 
54) discontinue the treatment as compared to the 200 mg group which had 22 percent of 
patients (n = 17) discontinue the treatment91.  While many patients did discontinue the 
study on the basis of AEs, it was noted that almost three-fifths of them left the study 
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based on the subjective grading of side effects as low to moderate levels of discomfort91.  
The AEs that were most influential in the decision of patients to discontinue the study 
were, in order of frequency: muscle spasms, dysgeusia, weight loss, and nausea.  Low 
discomfort AEs typical to the HHP inhibitors were seen across both groups: decreased 
weight, diarrhea, decreased appetite, fatigue, nausea, muscle spasms and alopecia66,79,83.  
A total of 144 patients had left the study by the point of primary analysis.  Two thirds 
(97) of these patients left due to withdrawn consent or as a result of AEs associated with 
treatment91. 
 The side effects experienced in the 200 mg group were more manageable, and 
were subjectively reported at lower levels of discomfort than those of the 800 mg group.  
This resulted in a lower discontinuation rate in the 200 mg group.  This group had a 
longer duration of exposure to the treatment because its participants showed more 
tolerance to the side effect profile associated with Sonidegib.  Increased tolerance is 
correlated with fewer AEs, fewer discontinuation events, and longer treatment durations. 
 Patients treated with Vismodegib or Sonidegib experienced a similar side effect 
profile, suggesting that these side effects are a class effect experienced with therapeutic 
use of SMIs of SMO66. 
Itraconazole/ATO 
Further research and clinical trials are needed to demonstrate that the long term 
administration of Itraconazole is safe in the doses that would be required for use as an 
anti-tumor therapeutic89.  But its side effect profile in short term, low-dose clinical 
treatments for fungal growth are already well understood.  The common side effects of 
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Itraconazole include low level discomforts similar to those seen in other SMO inhibitors 
including: muscle weakness, diarrhea and dysgeusia95.  These are generally mild and all 
adverse effects are reversible with discontinuation of the Itraconazole95. 
 Further research is needed to determine the side effect profile of Itraconazole or 
Itraconazole/ATO when used in combination therapy with Vismodegib or Sonidegib.  
Vismodegib and Sonidegib target the same SMO protein and have a very similar 
mechanism of action, and this often leads to an additive effect for two drugs used in 
combination therapy.  Itraconazole targets the same SMO protein as the others, but its 
mechanism of action is different, and so it remains to be seen whether the side effects of 
these drugs will show additive or synergistic interactions. 
 If the combination therapy with the drugs show the same level of side effects as 
those seen at the same dose with either of the drugs in individual use, then the side effects 
of combination therapy are additive.  An additive interaction for the side effects of 
combination therapy would have the same side effect profile of subjective patient 
discomfort as seen in treatment at the same dose with a single drug, and would not show 
an increase in the discontinuation rate among the patients.  If the combination therapy 
with the drugs shows a greater level of side effects than that seen at the same dose with 
either of the drugs in individual use, then the side effects of combination therapy are 
synergistic.  A synergistic interaction for the side effects of combination therapy would 
increase the patients’ subjective ratings of discomfort and would likely increase the 
discontinuation rate among the patients. 
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 Itraconazole/ATO will be indicated for the sub-group of patients with mBCC who 
show resistance to Vismodegib or Sonidegib and continued disease progression.  
Combination therapy with Itraconazole/ATO at the same effective dose as with 
Vismodegib or Sonidegib would likely show SMO inhibition with reduced side effects 
and a greater therapeutic effect. 
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DISCUSSION 
 
Current standard of care treatments for mBCC are SMO antagonists, including 
Vismodegib and Sonidegib, both of which have well established, quantitatively 
significant data supporting their success when used as a treatment for mBCC.  The 
majority of patients treated with Vismodegib experience clinical benefits from the 
therapeutic drug78, and the patients who reach an OR have shown both CRs and PRs93.  
Sonidegib is a useful treatment with a proven clinical record.  Sonidegib is a current 
standard of care treatment for mBCC with established quantitative data demonstrating its 
usefulness.  Sonidegib administered at a 200 mg dose greatly reduces the side effects of 
the drug seen with higher dose administration.  Fewer side effects leads to fewer patient 
discontinuations, and patients who remain in trials are more likely to see treatment effect.  
Sonidegib has comparable outcomes for CR and for PR at either dose, and so is a more 
useful treatment when administered at the lower dose74,91.  Multiple clinical trials 
demonstrate mBCC patients reaching a PR.  Measurements taken at follow-ups show that 
Sonidegib is also useful as a long-term treatment option, because patients continued to 
demonstrate responses in tumor reduction during extended periods of treatment 
administration. 
 The efficacy of SMIs of SMO are severely reduced by SMO mutations that cause 
resistance to treatment by lowering the binding-affinity of the drug for the DBP74,79.  
Clinicians working in clinical trials using current SMIs that work at the level of SMO 
should keep careful watch for the symptoms associated with a SMO mutation.  Patients 
who begin the study at disease control, followed by rapid progression of disease may be 
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harboring a SMO mutation that is refractory to the current standard of care treatment.  A 
patient with unusually rapid progression of disease has a poor prognosis, and could reach 
optimal therapeutic benefit when switched to combination therapy with 
Itraconazole/ATO.  Resistance to Itraconazole/ATO has not been documented in 
preclinical or clinical trials to date, and the treatment shows maximal therapeutic effect 
when administered after SMO resistance against Vismodegib or Sonidegib has been 
seen89. 
 A possible solution to the problem of SMO mutations and their resistance to 
treatment could be remedied with patient screenings.  Patients could be screened and 
sorted into populations that show SMO mutations resistant to Vismodegib or Sonidegib, 
and populations that show no SMO mutations refractory to Vismodegib or Sonidegib.  
Screening patients at the outset of a clinical trial to see whether they have the SMO 
mutations conferring drug resistance, then again during the course of treatment for 
patients with progression of disease, will increase the treatment success rate, and ensure 
that the drugs administered will be potent treatments: the right treatment, for the right 
patient at the right time.  The patient population without mutation, or harboring SMO 
mutations that have limited or no refractory effect on SMIs of SMO, can be given the 
standard of care treatments.  The patient populations whose personalized medicine 
screening reveals SMO mutations at locations known to be in the DBP and known to 
cause resistance to Vismodegib or Sonidegib, should be considered ineligible from 
treatment in the group receiving these medications.  Patients who have previously 
participated in systemic therapy with other SMOSMI should likewise be considered 
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ineligible from the SMOSMI treatment group.  Instead, they should receive treatment 
with Itraconazole/ATO, or with an entirely novel class of pathway modulator, provided 
that it works downstream of SMO and can be effective despite SMO mutations.  There 
are now many HPIs in preclinical and clinical trials, and these can be ethically 
administered as a treatment or combination treatment for mBCC.  This group would be a 
parallel control, and the success of treatments with multiple drugs could be evaluated 
under careful clinical conditions. 
 One promising drug candidate for the parallel control group is combination 
therapy with Itraconazole/ATO81,89,90,94,95.  Itraconazole/ATO works both at the level of 
SMO inhibition, but through a different mechanism and at a different binding site, and 
downstream of SMO, at the level of the GLI2 transcription factor.  Itraconazole exerts its 
effect through allosteric binding to SMO.  When a SMO inhibitor and Itraconazole are 
concurrently bound to SMO, the two drugs have an additive effect on SMO inhibition.  
This additive inhibition has been demonstrated experimentally in a medulloblastoma (a 
form of brain tumor) mouse model.  Medulloblastoma growth in mice is dependent on 
constitutive activation of the HHP causing continuous transcription of pathway-specific 
genes, and is inhibited by HPIs like Itraconazole.  Inhibition of tumor growth is even 
more potent when Itraconazole is administered in conjunction with another SMO 
antagonist89. 
 Itraconazole/ATO and the SMO inhibitors currently used in treatment for mBCC 
could be used in combinatorial therapy.  This combination therapy shows the potential to 
reduce tumor advance by up to 100 percent and to reduce tumor volume up to 50 percent.  
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If Itraconazole/ATO were to have additive effects with a SMO antagonist like 
Vismodegib or Sonidegib, this could increase the effect of current drug-based therapeutic 
modalities, and combinations of the administered ratios of these drugs could significantly 
decrease adverse side effects for patients in treatment.  These drugs show HHP inhibition 
even for SMO mutations resistant to treatment, because they work at a level downstream 
of SMO.  The combinatorial approach would work for all patients who show swift 
progression of disease caused by SMO mutations refractory to SMO inhibitors. 
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